Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years with or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)

Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy, Katia Abarca, Ilsiyar M. Khaertynova, Ron Dagan, Jennifer McCauley, Kyeongmi Cheon, Alison Pedley, Tina Sterling, Gretchen Tamms, Luwy Musey, Ulrike K. Buchwald

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Background: Adults with certain medical and behavioral factors are at increased risk for pneumococcal disease (PD). Sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-risk adults in some countries. Methods: This phase 3 trial evaluated the safety, tolerability, and immunogenicity of sequential administration of either V114 (a 15-valent PCV containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) or PCV13, followed 6 months later by PPSV23, in immunocompetent adults aged 18-49 years with or without predefined risk factors for PD (NCT03547167). Overall, 1515 participants were randomized 3:1 to receive either V114 or PCV13, followed by PPSV23. Results: Most common solicited adverse events (AEs) following administration of V114 or PCV13 as well as PPSV23 were injection-site pain and fatigue. The proportion of participants with AEs was comparable in both groups. V114 and PCV13 were immunogenic based on opsonophagocytic activity (OPA) geometric mean titers (GMTs) 30 days postvaccination for all serotypes contained in each respective vaccine. OPA GMTs to the 2 unique serotypes in V114 were robust in the V114 group. PPSV23 was immunogenic for all 15 serotypes contained in V114 in both vaccination groups, including 22F and 33F. Conclusions: V114 administered alone or sequentially with PPSV23 is well tolerated and immunogenic for all 15 serotypes, including those not contained in PCV13, in immunocompetent adults aged 18-49 years with or without certain medical or behavioral risk factors for PD. Clinical Trials Registration: NCT03547167 and EudraCT 2017-004915-38.

Original languageEnglish
Article numberofab605
JournalOpen Forum Infectious Diseases
Volume9
Issue number3
DOIs
StatePublished - Mar 2022

Keywords

  • 15-valent PCV
  • PCV13
  • pneumococcal vaccine
  • PPSV23
  • V114

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years with or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)'. Together they form a unique fingerprint.

Cite this